Immutep Announces First Patient Dosed In TACTI-004 Phase III Trial For Advanced Non-Small Cell Lung Cancer Combining Eftilagimod Alfa With KEYTRUDA And Chemotherapy

• First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for Immutep
• Global Phase III with efti will enrol approximately 756 patients at more than 150 clinical sites
• Trial results will inform potential marketing approval application in non-small cell lung cancer, one of the largest indications in oncology
  
  
  
   

 SYDNEY, AUSTRALIA, March 25, 2025 (GLOBE NEWSWIRE) --  Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the first patient has been successfully dosed in the Company's pivotal TACTI-004 Phase III trial. TACTI-004 will evaluate Immutep's eftilagimod alfa, a first-in-class MHC Class II agonist, in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and chemotherapy as first line treatment for patients with advanced or metastatic non-small cell lung cancer (1L NSCLC).

Dr. Ina Nordman, who treated the first patient at Calvary Mater Newcastle Hospital in Australia, stated, "We are very excited to participate in this important Phase III trial. Despite advancements in the treatment landscape for non-small cell lung cancer, there remains a high unmet need for new approaches that can safely extend patients' lives. The anti-cancer immune response driven by efti's unique mechanism of action as an MHC Class II agonist in combination with KEYTRUDA has led to strong efficacy across all PD-L1 levels with favourable safety in multiple lung cancer trials. We hope to see this study confirm the promise of this novel combination to provide patients with a powerful new treatment option."